{"id":7228,"date":"2024-06-11T10:00:00","date_gmt":"2024-06-11T08:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/"},"modified":"2024-06-11T10:00:00","modified_gmt":"2024-06-11T08:00:00","slug":"forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","title":{"rendered":"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes"},"content":{"rendered":"
\n

Nanexa AB meddelar idag att bolagets fas 1-studie f\u00f6r typ 2-diabetes har inletts med dosering av den f\u00f6rsta patienten. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system inom projektet NEX-22. Studien \u00e4r en doseskaleringsstudie som syftar till att utv\u00e4rdera farmakokinetisk profil, s\u00e4kerhet och tolerabilitet f\u00f6r olika doser.<\/strong><\/p>\n<\/div>\n

\n

Studien genomf\u00f6rs i Tyskland av CRO f\u00f6retaget Profil och \u00e4r den f\u00f6rsta kliniska studien d\u00e4r en l\u00e5ngverkande formulering av en GLP-1-substans baserad p\u00e5 PharmaShell studeras. Studien \u00e4r en \u00f6ppen fas 1-studie d\u00e4r administrering sker genom subkutan injektion av den l\u00e5ngverkande formuleringen. Studien \u00e4r designad att inkludera flera p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser. I studien inkluderas b\u00e5de kvinnor och m\u00e4n med typ 2-diabetes. Resultaten fr\u00e5n studien kommer ge viktig information f\u00f6r optimering av formuleringen inf\u00f6r kommande regulatoriska farmakokinetik- och effektstudier i patienter med Typ 2-diabetes.<\/p>\n

\u201cDenna studie \u00e4r en viktig milstolpe f\u00f6r NEX-22 och Nanexa. Ett l\u00e5ngtidsverkande l\u00e4kemedel f\u00f6rb\u00e4ttrar patientf\u00f6ljsamhet och har m\u00f6jlighet att \u00f6ka effekt och s\u00e4kerhet samt minska milj\u00f6p\u00e5verkan fr\u00e5n eng\u00e5ngsartiklar. Vi \u00e4r glada att samarbeta med Profil, som har s\u00e4rskild kompetens inom kliniska pr\u00f6vningar inom diabetes och fetma,\u201d s\u00e4ger G\u00f6ran Ando, styrelseordf\u00f6rande f\u00f6r Nanexa.<\/p>\n

Glukagonliknande peptid-1 (GLP-1) receptoragonister \u00e4r en klass av l\u00e4kemedel f\u00f6r behandling av typ 2-diabetes och fetma. I takt med \u00f6kande f\u00f6rekomst fetma och typ 2-diabetes i v\u00e4rlden v\u00e4xer ocks\u00e5 marknaden f\u00f6r GLP-1-receptoragonister. I en nyligen publicerad rapport uppskattar GlobalData att f\u00f6rs\u00e4ljningen av GLP-1-receptoragonister f\u00f6r marknaderna f\u00f6r typ 2-diabetes och fetma kommer att n\u00e5 \u00f6ver 125 miljarder dollar 2033 (1).<\/p>\n

Nanexa bed\u00f6mer att den \u00f6kade bekv\u00e4mligheten som det inneb\u00e4r med f\u00e4rre injektioner \u00e4n med dagens alternativ g\u00f6r bolagets formulering till ett attraktivt behandlingsalternativ f\u00f6r merparten av alla patienter.<\/p>\n

Referenser<\/strong>
(1) 68 market forecast f\u00f6r "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast, Global Data, May 2024<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag att bolagets fas 1-studie f\u00f6r typ 2-diabetes har inletts med dosering av den f\u00f6rsta patienten. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system inom projektet NEX-22. Studien \u00e4r en doseskaleringsstudie som syftar till att utv\u00e4rdera farmakokinetisk profil, s\u00e4kerhet och tolerabilitet f\u00f6r olika doser.<\/p>\n","protected":false},"template":"","class_list":["post-7228","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nF\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att bolagets fas 1-studie f\u00f6r typ 2-diabetes har inletts med dosering av den f\u00f6rsta patienten. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system inom projektet NEX-22. Studien \u00e4r en doseskaleringsstudie som syftar till att utv\u00e4rdera farmakokinetisk profil, s\u00e4kerhet och tolerabilitet f\u00f6r olika doser.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/\",\"name\":\"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-06-11T08:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","og_locale":"sv_SE","og_type":"article","og_title":"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB","og_description":"Nanexa AB meddelar idag att bolagets fas 1-studie f\u00f6r typ 2-diabetes har inletts med dosering av den f\u00f6rsta patienten. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system inom projektet NEX-22. Studien \u00e4r en doseskaleringsstudie som syftar till att utv\u00e4rdera farmakokinetisk profil, s\u00e4kerhet och tolerabilitet f\u00f6r olika doser.","og_url":"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","url":"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","name":"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-06-11T08:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/forsta-patient-doserad-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"F\u00f6rsta patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}